The activity on PARP7 and, indirectly on IFN-I response, was confirmed by the absence of regression on PARP7 KO tumor-bearing mice and reduced activity in CT26-tumor bearing immunodeficient NOG mice. Here, DDX53 is linked to neoplasm.